Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tivic Health Systems ( (TIVC) ).
On March 25, 2026, Tivic Health Systems reported its 2025 financial and operational results, marking completion of a major strategic pivot from consumer neuromodulation into a focused immunotherapy business built around its Entolimod platform and the creation of Velocity Bioworks as a wholly owned CDMO. The company exited its ClearUP consumer product line and suspended the non-core VNS program, relocated its headquarters to San Antonio and consolidated leadership with former Statera Biopharma CEO Michael K. Handley assuming Tivic’s CEO role in March 2026.
During 2025, Tivic acquired exclusive global rights to Entolimod for acute radiation syndrome, along with a substantial clinical and regulatory package, and advanced development readiness while engaging BARDA, DTRA, NIH and NIAID on potential funding and Strategic National Stockpile procurement, which could prove pivotal for future non-dilutive support. Management outlined a broader roadmap to use Entolimod as a beachhead into the multi-billion-dollar oncology supportive care market, with a near-term focus on neutropenia programs expected to enter physician-sponsored clinical trials later in 2026.
Financially, operating expenses rose to $7.9 million in 2025 from $4.5 million in 2024, driven by the launch of the biopharma business, expansion of Entolimod development efforts and the hiring of 45 staff to stand up Velocity Bioworks’ CDMO operations, resulting in an anticipated 2025 net loss of $8.8 million to $9.1 million versus $5.7 million a year earlier. Despite deeper losses, Tivic ended 2025 with $12.6 million in cash and $12.4 million in working capital, supported by a $16.3 million senior secured convertible note used to acquire biomanufacturing assets, giving the company a stronger balance sheet to pursue its immunotherapy and manufacturing strategy.
The establishment of Velocity Bioworks provides Tivic with vertically integrated biomanufacturing that is already reducing internal timelines and costs and is being positioned as a standalone CDMO to serve third-party biotech clients, offering a potential high-margin revenue stream and diversifying the company’s future cash flow profile. These moves collectively reposition Tivic as a higher-risk, development-stage biotech with meaningful exposure to U.S. government medical countermeasure funding channels and the oncology supportive care market, while legacy consumer health revenues have been discontinued.
The most recent analyst rating on (TIVC) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Tivic Health Systems stock, see the TIVC Stock Forecast page.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The score is primarily held down by weak financial performance (minimal revenue, persistent losses, and significant cash burn). Technicals also remain bearish with the stock below major moving averages and negative MACD. Strategic progress and improved cash on the earnings update provide partial support, but financing-related leverage/dilution risk and a negative earnings-based valuation keep the overall score low.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a development-stage immunotherapy company focused on biologics that activate innate immune pathways for cytoprotection and immune modulation in conditions driven by radiation, disease and immune dysregulation. Its lead candidate, Entolimod, a TLR5 agonist with FDA Fast Track and Orphan Drug designations for acute radiation syndrome, is complemented by next-generation agent Entolasta and supported by in-house and third-party biomanufacturing via its Velocity Bioworks CDMO subsidiary.
The company is targeting oncology supportive care indications such as chemotherapy-induced neutropenia and lymphocyte exhaustion, seeking to leverage Entolimod’s cytoprotective and immune-enhancing properties for broader therapeutic use. Velocity Bioworks provides Tivic with lower-cost, de-risked manufacturing and a potential external revenue stream while supporting its own drug pipeline and enhancing supply chain security.
Average Trading Volume: 240,077
Technical Sentiment Signal: Sell
Current Market Cap: $2.51M
See more insights into TIVC stock on TipRanks’ Stock Analysis page.